BeOne Medicines Ltd.
BeOne Medicines Ltd. (ONC): 115 pipeline candidates · 23 upcoming catalysts · ~15 mo cash runway · 84 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.7 months
D/E 0.80 · 4% dilution
Lead: Phase 3
115 candidates
23 upcoming, next in ~226d
0 buys · 24 sells (180d)
A transparent, data-derived signal for BeOne Medicines Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$27.4B
Cash
$4.9B
Quarterly Burn
$1.1B
Runway
14.7 mo
Revenue
$1.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (115 candidates)
| Drug | Phase |
|---|---|
| Acalabrutinib | Phase 4 |
| anti-diarrheal agent | Phase 1 |
| anticancer agents | Phase 3 |
| Anticancer Agents | Phase 3 |
| aromatase inhibitor | Phase 1 |
| Aromatase Inhibitor | Phase 1 |
| bat1706 | Phase 3 |
| bendamustine | Phase 3 |
| bendamustine | Phase 3 |
| Bendamustine | Phase 3 |
Showing 10 of 115 candidates. Sign up for full pipeline.
Upcoming Catalysts (23)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$8.26B
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 8,799,053 | $2.61B |
| primecap management co/ca/ | 4,975,181 | $1.48B |
| fmr llc | 3,693,610 | $1.10B |
| citadel advisors llc | 1,052,498 | $312.6M |
| hhlr advisors, ltd. | 1,034,306 | $307.2M |
| blackrock, inc. | 657,501 | $195.3M |
| siren, l.l.c. | 465,000 | $138.1M |
| morgan stanley | 464,472 | $137.9M |
| ubs group ag | 415,330 | $123.3M |
| bank of america corp /de/ | 405,273 | $120.4M |
Showing top 10 of 277 institutional holders of BeOne Medicines Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BeOne Medicines Ltd.'s pipeline?
BeOne Medicines Ltd. (ONC) has 115 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BeOne Medicines Ltd.'s lead drug candidate?
BeOne Medicines Ltd.'s most advanced tracked candidate is Acalabrutinib (Phase 4) for Chronic Lymphocytic Leukemia.
What is BeOne Medicines Ltd.'s next catalyst?
BeOne Medicines Ltd.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Eva" — expected June 18, 2026.
What is BeOne Medicines Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BeOne Medicines Ltd. has approximately 14.7 months of cash runway.
What is BeOne Medicines Ltd.'s market capitalization?
BeOne Medicines Ltd.'s market capitalization is approximately $27.4B.
Get the full picture on BeOne Medicines Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.